ArticleThe American journal of case reports2026
Long-Term Response to Pembrolizumab in Metastatic Metaplastic Breast Carcinoma: A Case Report.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Metaplastic breast carcinoma (MpBC), a rare subtype of breast malignancy characterized by low response rates to conventional chemotherapy, often presents as triple-negative breast cancer (TNBC). Recently, systemic therapy including immune checkpoint inhibitors (ICIs) has emerged as a promising treatment option for TNBCs in perioperative or metastatic settings. However, evidence regarding the efficacy of ICIs for MpBC remains limited. CASE REPORT A 52-year-old Japanese woman underwent radical surgery for primary MpBC of the breast, which confirmed the triple-negative subtype. Despite adjuvant chemotherapy with epirubicin and cyclophosphamide, metastases to the sternum and lungs developed during treatment. Because the initial surgical specimen was PD-L1-positive, the treatment was changed to chemoimmunotherapy consisting of pembrolizumab, gemcitabine, and carboplatin based on the KEYNOTE-355 trial. Although the precordial mass and multiple lung metastases temporarily increased in size soon after treatment initiation, the metastatic lesions subsequently showed marked shrinkage. The patient developed treatment-related adrenal insufficiency, rash, pruritus, and anemia, all categorized as Grade 2. Hydrocortisone replacement therapy was initiated for adrenal insufficiency, while pembrolizumab was continued without interruption. Ten months after treatment initiation, carboplatin plus gemcitabine was discontinued because of adverse events, including myelosuppression, and the patient was transitioned to pembrolizumab monotherapy. At 30 months after the initiation of chemoimmunotherapy, PET/CT showed only mild ¹⁸F-fluorodeoxyglucose uptake in the sternal metastasis, with no evidence of disease progression. CONCLUSIONS This report describes the successful treatment of metastatic MpBC with pembrolizumab-containing chemoimmunotherapy. Pembrolizumab combination therapy may be a promising treatment option for metastatic MpBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.